Deoxinojirimycin analogue or a pharmaceutically acceptable salt thereof, having the structure having the general structure (I): ** Formula ** in which R1, R3, R4 and R5 each independently comprise H or (CH2) nCH3 or X； n is 0-9； a, b, c, d, e are chiral centers that have an R or S configuration； and said deoxinojirimycin analog comprising at least one entity X, represented by: ** Formula ** comprising a large hydrophobic moiety Y and a spacer Z, according to which the large hydrophobic moiety is linked by the spacer to the nitrogen atom or atom of related carbon and in which the spacer Z is represented by (CH2) or, [(CH2) pP (CH2) q], in which 0>； = 0-9, p>； = 0-9, q>； = 0 -9, P>； = CH2 or CH2SCH2 or CH2OCH2 or ** Formula ** and the large hydrophobic Y moiety is selected from: ** Formula ** and said deoxinojirimycin analogue selected from the group consisting of: piperidines in which R2 >； = (CH2) nCH3 or X, R6>； = CH2OH or CH2OX ya>； = S, b>； = S, c>； = R, d>； = R, e>； = S beta-L-idopyranoside imitation, a>； = R , b>； = S, c>； = R, d>； = R, e>； = S alpha-L-idopyranoside imitation, piperidines in which R2>； = H, R6>； = CH2OH or CH2OX and b>； = S, c>； = R, d>； = R, e>； = S L-1-deoxyidopyranoside imitation.Análogo de desoxinojirimicina o una sal farmacéuticamente aceptable del mismo, que tiene la estructura que tiene la estructura (I) general:**Fórmula** en la que R1, R3, R4 y R5 comprenden cada uno independientemente H o (CH2)nCH3 o X； n es 0-9； a, b, c, d, e son centros quirales que tienen una configuración R o S； y comprendiendo dicho análogo de desoxinojirimicina al menos una entidad X, representada por:**Fórmula** que comprende un resto hidrófobo grande Y y un espaciador Z, según lo cual el resto hidrófobo grande está ligado por el espaciador al átomo de nitrógeno o átomo de carbono relacionado y en el que el espaciador Z está representado por (CH2)o, [(CH2)pP(CH2)q], en la que 0 >；= 0-9, p >；= 0-9, q >；= 0-9, P &
